Table 2.
Registries Reporting on Antiarrhythmic Drug Therapy and Cardioversion in AF
| Registry | Country | Years | Setting | Study Aim | Patient Characteristics | No. of AF Patients | Female (%) | Mean Age (±SD) | Paroxysmal AF (%) | CHADS2 (CHA2DS2VASC) |
|---|---|---|---|---|---|---|---|---|---|---|
| AFFECTS18–19 | USA | Mar 2005–Dec 2007 | Outpatients | Clinical practice patterns in management | AF with increased risk of stroke | 1461 | 46.3 | 66.2±13.3 | 79.7 | — |
| ATRIUM20 | Germany | 2009 | Outpatients | Management of AF in Germany | All stages of AF | 3667 | 42.0 | 72.0±9.0 | 27.1 | 2.2±1.3 (3.8±1.7) |
| CARAF I and II21 | Canada | 1991–2007 | Outpatients | Use of AADs in Canada from 1991 to 2007 | New‐onset paroxysmal AF | 1400 | — | — | 100 | — |
| GULF‐SAFE22 (Gulf Heart Association) | 6 Middle Eastern countries | Oct 2009–July 2010 | Emergency department | AF management in the Gulf | AF | 2043 | 48.0 | 57.0±16.0 | 17.0 | 2.1±0.5 |
| MADRE23 | Germany | 2010–2012 | Outpatients | Efficacy and tolerance of dronedarone in clinical practice | Paroxysmal or persistent AF | 191 | 44.5 | 63±9.9 | 62.5 | — |
| REALISE‐AF24 | 26 countries worldwide | Nov 2009–June 2010 | Outpatients | World‐wide management | At least 1 AF episode in the last 12 months | 10 523 | 44 | 66.6±12.2 | 24.8 | — |
| RECORDAF25–27 | 21 countries worldwide | May 2007–Apr 2008 | Inpatients/outpatients | World‐wide management | Recent‐onset AF | 5604 | 42.8 | 66±11.9 | 45.6 | — |
| RECORDAF‐Asia Pacific28 | 8 countries Asia/Pacific | Apr 2009–July 2010 | Outpatients | Management across Asia‐Pacific | Recently diagnosed AF | 2629 | 40 | 64±13 | 49 | — |
| RHYTHM‐AF29–30 | 10 countries worldwide | May 2010–Feb 2013 | Inpatients (cardioversion) | Antithrombotic therapy in relation to stroke risk and AF duration | AF patients suitable for cardioversion | 3940 | 38 | 66±12 | — | 3±2* |
AADs indicates antiarrhythmic drugs; ACTION, Acute Coronary Treatment and Intervention Outcomes Network; AF, atrial fibrillation.
*
Mean±SD.